Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026)
Jaguar Health (JAGX) reported Non-Current Deffered Revenue of $340000.0 for Q1 2026, down 33.33% year-over-year from $510000.0 in Q1 2025, and down 10.99% quarter-over-quarter from $382000.0 in Q4 2025.
Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 6 years of Non-Current Deffered Revenue data on file, last reported at $340000.0 in Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $340000.0, down 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $340000.0 (down 33.33% YoY), and the FY2025 annual result was $382000.0, down 30.92% from the prior year.
- Non-Current Deffered Revenue retreated to $340000.0 in Q1 2026 per JAGX's latest filing, from $382000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $680000.0 in Q1 2024 and troughed at $340000.0 in Q1 2026.
- A 3-year average of $510111.1 and a median of $510000.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue slipped 25.0% in 2025, then plunged 33.33% in 2026.
- A 3-year view of Non-Current Deffered Revenue shows it stood at $553000.0 in 2024, then slumped by 30.92% to $382000.0 in 2025, then fell by 10.99% to $340000.0 in 2026.
- Business Quant data shows JAGX's Non-Current Deffered Revenue at $340000.0 in Q1 2026, $382000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 340,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 553,000.00 |
| Sep 30, 2024 | 595,000.00 |
| Jun 30, 2024 | 638,000.00 |
| Mar 31, 2024 | 680,000.00 |
| Jun 30, 2017 | 7,271.00 |
| Mar 31, 2017 | 7,114.00 |
| Dec 31, 2016 | 6,956.00 |
| Sep 30, 2016 | 6,799.00 |
| Jun 30, 2016 | 6,642.00 |
| Mar 31, 2016 | 4,981.00 |
| Dec 31, 2015 | 3,321.00 |
| Sep 30, 2015 | 1,660.00 |